Hong Kong Moves Toward Mandatory Medical Device Regulation: What MDACS Procurement Changes Mean for Manufacturers

Hong Kong is taking a significant step toward strengthening its medical device regulatory framework, with recent developments signalling a shift from a voluntary system toward more structured regulatory oversight.

In March 2026, the Hong Kong Department of Health implemented Stage C of its medical device procurement framework, introducing new requirements that directly impact how medical devices are supplied to the public sector.

This update marks an important evolution in Hong Kong’s regulatory landscape and has immediate implications for manufacturers seeking market access.

A Shift in the Role of MDACS

The Medical Device Administrative Control System (MDACS) has historically operated as a voluntary listing system in Hong Kong, allowing manufacturers to register their devices without making market entry a legal requirement.

However, under the latest update, the MDACS listing has effectively become mandatory for participation in public procurement.

Medical devices that are not listed under MDACS are no longer eligible for supply to public healthcare institutions, even if an application for listing is currently under review.

This represents a clear shift in how the system is being applied in practice.

What Has Changed in March 2026?

With the implementation of Stage C, the Hong Kong Department of Health now requires that:

• Medical devices must be fully listed under MDACS to qualify for public procurement

• Pending applications are no longer sufficient for eligibility

• Only approved and listed devices can be supplied to public sector entities

The requirement applies to:

• Class II, III, and IV medical devices

• Class B, C, and D in vitro diagnostic (IVD) devices

These categories include medium- to high-risk devices, which are commonly used across healthcare systems.

Why This Matters for Medical Device Manufacturers

This development has significant commercial and regulatory implications.

1. MDACS Listing Becomes Commercially Essential

While still technically voluntary, MDACS listing is now a practical requirement for companies targeting public healthcare institutions in Hong Kong.

2. Increased Regulatory Pressure

Manufacturers must ensure that their products are fully listed before participating in procurement processes, requiring earlier planning and submission.

3. Potential Market Access Limitations

Companies without MDACS-listed products may face restricted access to one of Hong Kong’s most important healthcare channels.

A Step Toward Mandatory Regulation?

This update reflects a broader regulatory trend in Hong Kong.

Although the system remains officially voluntary, the introduction of procurement-linked requirements suggests a gradual move toward a more formal and potentially mandatory regulatory framework in the future.

For manufacturers, this signals the importance of treating MDACS not as optional, but as a core component of market entry strategy.

Strategic Considerations for Market Entry

To adapt to this evolving environment, companies should consider:

• Initiating the MDACS listing well in advance of market entry plans

• Ensuring full compliance with technical documentation and classification requirements

• Monitoring further regulatory developments that may expand mandatory elements

• Aligning commercial strategies with public procurement eligibility criteria

Proactive regulatory planning will be key to maintaining competitiveness in the Hong Kong market.

Hong Kong’s Direction: Strengthening Oversight While Enabling Access

The latest changes demonstrate Hong Kong’s commitment to improving the safety, quality, and traceability of medical devices within its healthcare system.

At the same time, they reflect a broader regional trend toward stronger regulatory controls and increased accountability for manufacturers.

For companies operating in Asia, Hong Kong’s evolving framework serves as an important indicator of how regulatory systems may continue to develop in the region.

How ARQon Can Support

At ARQon International Group, we support medical device companies in navigating evolving regulatory environments across Asia, including Hong Kong.

Our services include:

• MDACS listing strategy and submission support

• Regulatory intelligence and monitoring

• Market entry and expansion planning

• Compliance with regional regulatory requirements

As regulatory frameworks continue to evolve, having the right strategy and expertise is essential to achieving efficient and successful market access.